Right here, we describe a pharmacogenetics tactic which allows to selectively and reversibly inactivate LC neurons working with Designer Receptors Completely Activated by Designer Drugs (DREADD). We show that the expression on the hM4Di DREADD is often limited to noradrenergic LC neurons Which the level of LC inhibition may be modified by adapting